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Abstract 
Purpose: We compared a restrictive fluid management strategy to usual care among critically ill patients with acute 
kidney injury (AKI) who had received initial fluid resuscitation.
Methods: This multicenter feasibility trial randomized 100 AKI patients 1:1 in seven ICUs in Europe and Australia. 
Restrictive fluid management included targeting negative or neutral daily fluid balance by minimizing fluid input 
and/or enhancing urine output with diuretics administered at the discretion of the clinician. Fluid boluses were 
administered as clinically indicated. The primary endpoint was cumulative fluid balance 72 h from randomization.
Results: Mean (SD) cumulative fluid balance at 72 h from randomization was − 1080 mL (2003 mL) in the restric-
tive fluid management arm and 61 mL (3131 mL) in the usual care arm, mean difference (95% CI) − 1148 mL (− 2200 
to − 96) mL, P = 0.033. Median [IQR] duration of AKI was 2 [1–3] and 3 [2–7] days, respectively (median difference − 1.0 
[− 3.0 to 0.0], P = 0.071). Altogether, 6 out of 46 (13%) patients in the restrictive fluid management arm and 15 out of 
50 (30%) in the usual care arm received renal replacement therapy (RR 0.42; 95% CI 0.16–0.91), P = 0.043. Cumulative 
fluid balance at 24 h and 7 days was lower in the restrictive fluid management arm. The dose of diuretics was not dif-
ferent between the groups. Adverse events occurred more frequently in the usual care arm.
Conclusions: In critically ill patients with AKI, a restrictive fluid management regimen resulted in lower cumulative 
fluid balance and less adverse events compared to usual care. Larger trials of this intervention are justified.
Keywords: Acute kidney injury, Critically ill, Fluid balance, Restrictive fluid management
Introduction
Many critically ill patients develop acute kidney injury 
(AKI). AKI is associated with an increased risk of adverse 
outcomes [1, 2]. Current management of AKI remains 
supportive and includes optimization of hemodynam-
ics and fluid status, avoidance of nephrotoxins [3] and, 
in severe cases, renal replacement therapy (RRT) [1, 2]. 
Novel therapies are being evaluated in cardiac surgical [4] 
and septic patients [5], but no specific pharmacological 
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therapies for general intensive care unit (ICU) patients 
are currently available.
While fluid therapy is the traditional cornerstone of 
AKI prevention and treatment [6], patients with AKI 
are also especially prone to develop fluid overload [7]. 
Such fluid overload is associated with increased mortal-
ity [7–11] and progression of AKI [12, 13]. Thus, a more 
restrictive fluid management approach among adequately 
resuscitated patients with AKI might improve outcomes 
by reducing congestion and improving kidney and other 
organ function. Notably, a feasibility trial in septic shock 
patients comparing restrictive fluid resuscitation versus 
usual care reported a lower risk of worsening of AKI in 
the restrictive group [14].
Trials among general ICU patients [15], or those with 
sepsis [14, 16] or acute respiratory distress syndrome 
(ARDS) [17] have found various fluid restrictive strategies 
to be safe. Among patients undergoing major abdominal 
surgery, however, restrictive intra- and post-operative 
fluid resuscitation and management compared to usual 
care increased the risk of AKI [18]. Thus, research inves-
tigating the role of restrictive fluid management specifi-
cally in critically ill patients with AKI has been identified 
as a research priority [3, 19, 20]. To date, such trials have 
not been performed.
Accordingly, we conducted a multinational, unblinded, 
randomized, controlled, feasibility pilot trial comparing 
a restrictive fluid management (RFM) regimen to usual 
care among ICU patients with AKI to study the feasibil-
ity of such intervention in terms of separation, safety, and 
compliance. We tested the hypothesis that the proposed 
RFM regimen would lead to a lower cumulative fluid bal-
ance at 72 h post-randomization.
Methods
Trial design
We conducted an investigator-initiated, multicenter, 
unblinded, randomized, controlled, parallel pilot feasibil-
ity study (clinicaltrials.gov identifier NCT03251131) in 
five European and two Australian ICUs. The trial proto-
col and statistical analysis plan were published prior to 
completion of data collection [21]. In each participating 
site, the trial was approved by the relevant research eth-
ics committee prior to commencing screening. Depend-
ing on local practices and ethics approval, we obtained 
written informed consent either prior to enrollment 
from patient or proxy, or alternatively a deferred consent 
with written informed consent obtained from patient or 
proxy as soon as possible. If consent was not granted or 
withdrawn, approval of using data collected that far was 
sought. Trial was performed according to the Declaration 
of Helsinki and its later amendments.
We randomized patients to either RFM or usual care 
using an electronic platform with allocation ratio of 1:1. 
Severity of AKI (stage 1 vs stage 2 or 3 according to the 
Kidney Diseases: Improving Global Outcomes (KDIGO) 
criteria [3]) and presence of clinical signs of fluid accu-
mulation (defined by peripheral pitting edema and/or 
positive fluid balance with P/F ratio less than 200 mmHg) 
served as stratification variables. We used permuted 
blocks of varying size (2–4). Due to the nature of inter-
vention, only the statistician conducting the data analysis 
remained blinded to treatment allocation.
Patients
We included patients who (1) were 18 years or older and 
admitted to critical care with an arterial line in place, 
(2) were in critical care for at least 12 but no more than 
72  h (3) had AKI but were not receiving RRT, (4) were 
judged by the treating clinician not to be hypovolemic, 
and (5) were likely to remain in critical care for 48 h after 
randomization.
We defined AKI according to the following criteria: (1) 
increase in plasma creatinine 1.5 times or more above 
baseline without a decline of 27umol/L or more from 
the last preceding measurement and/or (2) overall urine 
output less than 0.5 ml/kg/h (or 6 ml/kg) for the previous 
12 h. Exclusion criteria are listed in Fig. 1. The Electronic 
Supplementary Material (ESM) Tables S1 and S2 present 
detailed definitions of the eligibility criteria.
Interventions
The trial intervention (RFM) consisted of a bundle of 
treatment recommendations for clinicians treating the 
trial patients. The overall aim was to reach negative fluid 
balance on the days following randomization. These rec-
ommendations included, first, restricting total daily fluid 
input only to medications and nutritional fluids (enteral 
or parenteral) and blood products (if clinically neces-
sary). Second, use of maintenance intravenous fluids was 
permitted only if enteral nutrition was not tolerated and 
parenteral nutrition contraindicated. Third, fluid bolus 
therapy could be given as clinically deemed necessary. 
Fourth, matching fluid output (with unrestricted use of 
diuretics) to fluid input whenever possible to achieve a 
preferably negative cumulative fluid balance but always 
Take‑home message 
Among critically ill patients with acute kidney injury, a fluid restric-
tive management regimen as compared to usual care led to a lower 
cumulative fluid balance after 72 h from randomization. Adverse 
events were more frequent in the usual care arm.
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less than 300  mL/day. Fifth, if the fluid balance target 
could not be achieved by such means, consideration of 
RRT to remove the required fluid. Commencing RRT was 
not mandated in the trial and, if RRT was not considered 
clinically desirable, the protocol indicated acceptance of a 
less than targeted fluid balance temporarily (for 24 h) up 
to 900 mL.
In the usual care group, fluid management was at the 
discretion of the treating clinical team.
Fluid balance was calculated by subtracting total fluid 
output (urine output, losses to drains, losses from gas-
trointestinal tract, ultrafiltration by RRT) from total fluid 
input (intravenous and oral). Insensible losses were not 
considered. The intervention period was 7 days from ran-
domization or until ICU discharge whatever occurred 
first.
Outcomes
The primary outcome was cumulative fluid balance 
at 72  h after randomization adjusted for stratification 
variables [21, 22]. Secondary outcomes included dura-
tion of AKI in days defined by the KDIGO creatinine 
and urine output criteria (truncated at ICU discharge 
or 14  days whichever came first), number of patients 
requiring RRT (truncated at 14  days, including initia-
tion of RRT after ICU discharge), cumulative fluid bal-
ance at 24 h after randomization and at ICU discharge 
(or truncated at 7  days if ICU stay exceeded 7  days), 
and cumulative dose of diuretics (furosemide) during 
the intervention period (while in the ICU, maximum 
of 7 days) adjusted for the duration of the observation 
period.
Exploratory outcomes included days free of mechani-
cal ventilation and alive at 14  days, days free of vaso-
pressors and alive at 14  days, days free of ICU and 
alive at 14 days, days free of RRT and alive (assessed at 
90 days), 90-days dialysis dependence and 90-days mor-
tality. The safety and feasibility outcomes included the 
number of patients with one or more (serious) adverse 
events (AE) and reactions in both arms (detailed defi-
nitions are provided in Table  S3), screened versus 
recruited patients ratio, recruitment rate (patients/
center/month), and protocol compliance (number of 
patients with protocol violations in both arms).
Fig. 1 Flowchart of trial patients. ICU intensive care unit, RRT renal replacement therapy. a Diabetic ketoacidosis, non-ketotic coma, severe burns or 
other clinical reason determined by the medical staff. b Glomerulonephritis, vasculitis, acute interstitial nephritis, or post-renal obstruction. c Includ-
ing two exclusion criteria that were removed in a protocol amendment in April 2018 (1) Metformin-induced lactic acidosis or acute liver failure 
(n = 8) (2) AKI stage 2 or greater is known to have been present for > 48 h (n = 14). These criteria were amended to clarify the exclusion criteria
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Statistical analysis
Details of statistical analysis plan have been published 
[21]. We estimated that 50 patients per arm would be 
required to show a difference of 1200 mL in the primary 
outcome between treatment arms with a two-sided alpha 
of 0.05 and power exceeding 80%. Based on unpublished 
data among AKI patients in the FINNAKI study [1], we 
estimated that cumulative fluid balance at 72 h would be 
2700 mL in the usual care group, and thus 1500 mL in the 
fluid restrictive group (both with a SD of 2000 mL).
We performed the primary analysis on the intention-
to-treat (ITT) population defined as all randomized 
subjects with consent to use data in the analysis. An 
additional sensitivity analysis was conducted in the 
per-protocol population, defined as the ITT popula-
tion after exclusion of subjects who experienced proto-
col violation(s) or stayed in the ICU for less than 48  h 
post-randomization.
The primary, secondary, and exploratory outcomes 
were adjusted for the stratification variables [22] (mild 
vs severe AKI and presence/absence of clinical signs of 
fluid accumulation) using two-tailed logistic regression 
(dichotomous outcomes) or a linear model (continuous 
outcome variables, mean or median regression model). 
We report risk ratios (RR) with 95% confidence intervals 
(CIs) or difference in means/median with 95% CIs.
We used Shapiro–Wilk test for continuous variables to 
assess assumption of normality. We set the statistical sig-
nificance to 0.05 and report two-sided P values. Analyses 




Between October 2017 and January 2020, we screened 
997 patients and randomized 102 patients. One patient 
in each group declined consent leaving 100 patients for 
analysis. Randomization occurred at a median [IQR] 
30.7 [20.4–46.2] hours after ICU admission. Forty-
nine patients (49%) were assigned to the RFM arm and 
51 (51%) to the usual care arm. Figure  1 presents the 
patient flow. Further, two patients in the RFM arm and 
three patients in usual care arm withdrew consent and 
their data obtained until withdrawal were included in the 
analysis.
Patient baseline characteristics and status at randomi-
zation were well-balanced (Table  1). The most frequent 
reasons for ICU admission were cardiac arrest (8.2%), 
septic shock (7.2%), and gastrointestinal perforation/rup-
ture (7.2%). Suspected etiology of AKI was multifactorial 
in 55 (55%) patients. Table S5 presents the observed AKI 
risk factors.
Primary, secondary, and exploratory outcomes
At 72  h, 66 (66%) patients were still in ICU, while 29 
(29%) were discharged, four were deceased (one in RFM 
arm and three in usual care), and one had withdrawn 
consent for further data collection. The median length 
of stay from randomization to discharge among these 34 
patients was 49.2 [32.6–51.9] in RFM arm and 51.0 [29.3–
60.2] hours in the usual care arm. The primary outcome 
was assessed after a median [IQR] 72.0 [53.9–72] hours 
from randomization. Figure  2 presents fluid input and 
output data along with daily fluid balance in both arms. 
Table  2 presents the primary and secondary outcomes. 
The mean difference (95% CI) in cumulative fluid balance 
at 72 h was − 1148 (− 2200 to − 96) mL, P = 0.033. There 
was no difference in duration of AKI but fewer patients 
in the RFM group received RRT compared to the usual 
care group. Two additional patients in the usual care arm 
commenced RRT after day 14. Cumulative fluid balance 
at 24  h and at ICU discharge or on day 7 were signifi-
cantly lower in the RFM group. Diuretics were adminis-
tered to 35 (71.4%) in the RFM group and 38 (74.5%) in 
the usual care group. The median [IQR] day number of 
first administration of diuretics was 1 [1] in both groups. 
There were no differences in the cumulative doses of diu-
retics adjusted for observation days. The crude primary 
outcome was in line with the adjusted analysis (Table S6). 
There were no significant differences in the adjusted or 
unadjusted exploratory outcomes (adjusted in Table  3, 
crude in Table  S7). Figure S1 presents the daily SOFA 
score according to treatment allocation.
Safety and feasibility outcomes
Eleven (22.4%) patients in the RFM group and 25 (49%) 
in the usual care group experienced one or more AE (risk 
ratio 0.46; 95% CI 0.36–0.63, P = 0.001). Serious adverse 
events (SAE) were observed in six (12.2%) patients ran-
domized to RFM group and in 16 (31.4%) randomized to 
usual care group (RR 0.39; 95% CI 0.15–0.86, P = 0.031). 
Table  S8 provides a detailed description of AEs and 
SAEs. Most events were related to disturbances in serum 
electrolyte concentrations and RRT. The median [IQR] 
number of patients recruited per center/month was 0.8 
[0.5–1.7] (Figure S2).
Fluid protocol and protocol violations
Protocol violations occurred in 18 (36.7%) in the RFM 
arm and in 5 (9.8%) in the usual care arm. In the RFM 
arm, use of excess maintenance fluid was the most fre-
quently observed protocol violation in 9 (18.4%) patients 
(Table S9). Moreover, five patients in the RFM arm had 
a protocol suspension for the following reasons: hyper-
natremia (n = 2), need for surgery (n = 1), complete 
heart block (not considered to be attributable to study 
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intervention) (n = 1), and withdrawal of consent (n = 1). 
One patient in the usual care arm had protocol suspen-
sion as overall ICU care was withdrawn.
Per‑protocol analysis
Twenty-three patients (46.9% of 49) in the RFM arm and 
37 (72.5% of 51) in the usual care arm were included in 
the per-protocol analysis. The primary or secondary out-
come variables were not different in the per-protocol 
population except for fluid balance at 24 h (Table S10).
Discussion
Key findings
In this multicenter, multinational, unblinded, rand-
omized, controlled, feasibility pilot study involving 100 
critically ill patients with AKI who were considered 
adequately resuscitated, we assessed whether, compared 
to usual care, a restrictive fluid management regimen 
would lead to a meaningful difference in cumulative fluid 
balance after 72  h from randomization without signals 
of harm. We found the RFM protocol to be effective in 
terms of achieving a lower cumulative fluid balance at 
72  h compared to usual care. Moreover, patients in the 
RFM arm received RRT less frequently and had fewer 
adverse events than patients in the usual care arm.
Relationship with previous studies
No randomized controlled trial has studied a RFM regi-
men among critically ill patients with AKI.
Table 1 Patient characteristics
The number of missing data is presented in Table S4 in the Electronic Supplementary Material
AKI acute kidney injury, SAPS simplified acute physiology score, SOFA sequential organ failure assessment
a Data of one or several SAPS II score subcomponents were missing from 11 patients in the RFM group and 15 in the usual care group. Their scores are omitted here
b The hepatic subcomponent score was assumed to be 0 in those 4 in RFM group and 3 in the control group with missing bilirubin values
c Definition of the stratification variable: presence of peripheral pitting edema and/or positive fluid balance with P/F ratio less than 200 mmHg




Age, median [IQR], years 71 [60–77] 64.5 [56.2–74]
Male sex, n (%) 30 (62.5) 36 (70.6)
Body mass index, median [IQR], kg/m2 25.6 [22.8–29.5] 26.4 [22.7–31.1]
Hypertension, n (%) 26 (54.2) 32 (65.3)
Diabetes, n (%) 24 (50) 33 (66)
Chronic heart failure, n (%) 6 (12.5) 7 (14)
Coronary artery disease, n (%) 9 (18.8) 16 (31.4)
Chronic obstructive pulmonary disease, n (%) 8 (16.7) 14 (27.5)
Chronic kidney disease, n (%) 5 (10.6) 6 (11.8)
Chronic liver disease, n (%) 4 (8.3) 3 (5.9)
Surgical ICU admission, n (%) 22 (44.9) 20 (40)
Emergency ICU admission, n (%) 37 (75.5) 41 (82)
Time from hospital admission to ICU admission, median [IQR], days 1 (0.1–4) 0.9 (0.2–2.9)
Time from ICU admission to randomization, median [IQR], h 33.3 (21.4–45.9) 30 (20.3–46)
Data at randomization
 AKI inclusion criteria
  Creatinine 25 (51) 28 (54.9)
  Urine output 10 (20.4) 8 (15.7)
  Creatinine and urine output 14 (28.6) 15 (29.4)
  SAPS II score, median  [IQR]a 41.5 [31.3–51.5] 43 [30–50]
  SOFA score, median  [IQR]b 9 [8–11] 9 [7–11]
  AKI stage 2 to 3 (stratification), n (%) 31 (63.3) 33 (64.7)
  Fluid overload present (stratification), n (%)c 21 (42.9) 22 (43.1)
  Respiratory supportmechanical ventilation, n (%) 24 (49) 33 (66)
  Vasoactives, n (%) 30 (61.2) 37 (72.5)
  Sepsis, n (%) 27 (55.1) 30 (58.8)
  Septic shock, n (%) 5 (10.2) 9 (17.7)
  Cumulative fluid balance from ICU admission to randomization, mean (SD), mL 2437 (2103) 1982 (2434)
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Fig. 2 Daily fluid input, fluid output and daily fluid balance from randomization in restrictive versus usual care. Boxplots represent median with IQR 
and range in mL. Bars present the daily balance (not cumulative) in mL. RFM restrictive fluid management
Table 2 Primary and secondary outcomes (adjusted for stratification variables)
AKI acute kidney injury, RRT renal replacement therapy
a Adjusted (severity of AKI and presence of fluid overload) difference in means/median or risk ratio with 95% CIs
b P value derived from regression model adjusted for stratification variables (severity of AKI and presence of fluid accumulation)
c The last available value for cumulative balance was analyzed for all patients even if ICU discharge or consent withdrawal would have occurred before endpoint was 
fulfilled
d Truncated at 7 days, ICU discharge, or consent withdrawal. Data missing for three patients-receiving restricted fluid management and one in usual care
e Truncated at 14 days (RRT provided post-ICU discharge included)
f Per oral furosemide dose divided by 2 to make it comparable to intravenous doses
Outcome Restrictive fluid 
management 
(n = 49)
Usual care  
(n = 51)
Restrictive fluid manage‑
ment vs usual care (95% 
CI)a
P  valueb
Cumulative fluid balance at 72 h from randomization, mean (SD) 
 mLc
 − 1080 (2003) 61 (3131)  − 1148 (− 2200; − 97) 0.033
Duration of AKI (days), median  [IQR]d 2 [1–3] 3 [2–7]  − 1 (− 3; 0) 0.071
Number of patients-receiving RRT, n (%)e 6/46 (13) 15/50 (30) 0.42 (0.16; 0.91) 0.043
Cumulative fluid balance at 24 h from randomization, mean (SD) 
 mLc
 − 416 (1194) 409 (1566)  − 822 ( − 1381; − 264) 0.004
Cumulative fluid balance at ICU discharge/day 7, mean (SD)  mLc  − 2166 (2988)  − 650 (4469)  − 1532 (− 3036; − 29) 0.046
Cumulative dose of furosemide per day, median [IQR]  mgf 0 (0–19) 1.4 (0–26.2) 0 (− 11; 5.7) 0.700
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The FACTT trial, conducted from 2000 to 2005, com-
pared conservative fluid management to liberal therapy 
in patients with ARDS and found no difference in 60-day 
mortality, but reported shorter duration of mechanical 
ventilation and a trend toward less RRT in the conserva-
tive arm [17]. Furthermore, a sub-analysis of patients 
with AKI found an association with high cumulative fluid 
balance and mortality [9]. In the FACTT, the cumulative 
fluid balance on day three (corresponding to the primary 
endpoint in the current analysis) was about 150 mL in the 
conservative arm and about 5000 mL in the liberal arm, 
both more positive than in our study [23]. Moreover, we 
observed a much lower actual fluid balance in the usual 
care group than we had assumed based on data collected 
in 2011–2012. Such a shift towards more restrictive fluid 
management practices among the critically ill has been 
reported also in another RFM pilot trial [24].
Most interventional fluid trials in the critically ill have 
concentrated on modifying fluid administration [14, 15, 
25–28] or enhancing fluid output with diuretics and/or 
ultrafiltration [29]. Our approach of combining the two 
sides of the coin in one trial gave the treating clinician 
more tools to individualize fluid therapy while still suc-
cessfully targeting a clinically meaningful outcome meas-
ure. For example, the CLASSIC pilot trial among patients 
with septic shock achieved a difference in the adminis-
tered resuscitation fluid but not in the total fluid balance 
[14]. Notably, fluids other than resuscitation fluid repre-
sent the largest proportion of the administered fluids [30, 
31] even in patients with shock [32].
A dynamic intervention bundle such as ours may be 
more suitable for AKI patients who represent a het-
erogeneous group of patients with some having severely 
reduced urine output significantly affecting the achiev-
able fluid output while others have a creatinine rise but 
preserved urine output. A French stepped wedge cluster 
RCT is assessing another dynamic approach among gen-
eral ICU patients [33]. The trial intervention involves 
fluid restriction and/or enhancement of fluid output 
to achieve a daily weight loss of 0.5  kg in patients with 
increasing daily weight [33]. However, no results are 
yet available. A pilot study among septic shock patients 
reported a rather large but non-significant difference 
between restrictive and usual care without any signals of 
harm, but the trial was stopped early as the predefined 
endpoint of a—500  mL—difference in mean daily fluid 
balance was not met [24].
Study implications
Our results showed that, in ICU patients with AKI who 
are considered not to be hypovolemic, using a combined 
strategy targeting control of daily fluid balance is both 
feasible and safe. Adverse events were more frequent in 
the usual care arm, possibly related to more frequent use 
of RRT in this group. Moreover, the trial provides ini-
tial support to the hypothesis that fluid accumulation is 
linked to important outcomes among AKI patients such 
as need for RRT, a hypothesis that should be studied in 
larger clinical trials.
A quarter of excluded patients were ineligible due to 
being still considered intravascularly hypovolemic albeit 
having stayed in the ICU for at least 12  h. This is an 
important patient cohort that should be considered when 
designing future RFM trials. Potentially, these patients 
could be enrolled, if the RFM protocol included a well-
defined starting trigger after correction of hypovolemia 
such as using passive leg raising or other dynamic tests to 
assess fluid responsiveness [34, 35].
Strengths and limitations
Obvious strengths to our study include randomization 
to minimize selection bias and a multinational approach 
Table 3 Exploratory outcomes (adjusted for stratification variables)
a Adjusted (severity of AKI and presence of fluid overload) difference in means/median with 95% CIs
b P value derived from regression model adjusted for stratification variables (severity of acute kidney injury and presence of fluid accumulation)
c Truncated at 14 days or ICU discharge. Potential ICU readmissions not included. Data not available for two patients-receiving restrictive fluid management and for 
one receiving usual care
d Data not available for two patients in both groups
Outcome Restrictive fluid 
management
Usual care Restrictive fluid management 
vs usual care (95% CI)a
P  valueb
Days alive and free of mechanical ventilation, median  [IQR]c 13 (9–14) 11.5 (1.5–14) 0 (− 1; 6) 0.284
Days alive and free of vasopressors, median [IQR] c 12 (10–14) 11.5 (7–13) 1 (0; 2) 0.072
Days alive and free of ICU treatment, median [IQR] c 8 (3–11) 2.5 (0–11) 2 (0; 6) 0.106
Days alive and free of RRT at 90 days, median  [IQR]d 90 (85–90) 90 (33–90) 0 (0; 14) 0.145
Dialysis dependence at 90-days, n (%) 0/46 (0) 1/49 (2) 0.34 (0.01; 8.55) 1.000
90-day mortality, n (%) 9/46 (19.6) 13/49 (26.5) 0.74 (0.35; 1.46) 0.387
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allowing simultaneous feasibility assessment in multiple 
locations with potentially different fluid treatment prac-
tices and increasing external validity. In addition, we used 
a treatment bundle targeting both fluid input and output 
to maximize the efficacy of the intervention, a dynamic 
two-pronged approach, which increased flexibility and 
allowed for individualization of treatment according to 
perceived patients’ needs. Moreover, we collected data 
on multiple potential adverse events daily to be able to 
reliably identify any signal of harm potentially associated 
with RFM.
We acknowledge several limitations. First, blinding of 
the intervention was not possible due to its nature. Sec-
ond, calculated fluid balance is not an exact measure, 
as measurement of fluid output in patients with high 
insensible losses (such as losses to wound dressing) is 
not exact. Thus, the actual fluid balance of the included 
patients in both groups may be lower than reported here. 
Third, we observed protocol violations in terms of use of 
excessive maintenance fluid. This may signal the presence 
of local practices [30, 32] that need to be better addressed 
in future trials. Fourth, we excluded patients with treat-
ment limitations albeit many from this heterogenous 
group could potentially have been enrolled. Nonetheless, 
we observed a signal for positive patient-centered out-
comes in the frequency of RRT, which implies that fluid 
restriction may have an effect on clinical outcomes.
Conclusions
In a pilot multicenter, international, randomized, con-
trolled trial of critically ill patients with AKI who were 
considered adequately fluid resuscitated, a restrictive 
fluid management regimen was feasible, resulted in fewer 
adverse events than usual care, and delivered a significant 
separation in fluid balance. The results also suggested 
benefit in terms of patient-centered outcomes implying 
that this intervention should now be studied in larger 
trials.
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